Abstracts tagged "rheumatoid arthritis (RA) and treatment"

Abstract Number: 350 • 2014 ACR/ARHP Annual Meeting
Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies
Reena Khianey¹, Cristina Rozo², Sanjay Gupta³, Vivian P. Bykerk¹, Susan M. Goodman¹ and Alessandra B. Pernis⁴, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²535 East 70th Street, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Research, Hospital for Special Surgery, New York, NY
Background/Purpose: Rho-associated protein kinases (ROCKs) regulate cytoskeletal reorganization and gene expression through protein phosphorylation, and are implicated in the pathogenesis of a wide range of…
Abstract Number: 2441 • 2014 ACR/ARHP Annual Meeting
Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis
Maria Celeste Orozco¹, Maria Florencia Marengo², Christian A. Waimann², Ana Inés Marcos³, Amelia Granel³, Sofia Velez⁴, Federico Zazzetti⁵, Juan C. Barreira⁶, Paula Kohan⁷, Oscar L. Rillo⁸, María Victoria Collado⁹, Graciela Gómez¹⁰, Ricardo V. Juárez¹¹, Veronica Lencina¹², Andrea D'Orazio¹³, Gustavo Rodriguez Gil¹³, Mariana Salcedo¹⁴ and Gustavo Citera¹⁵, ¹Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Rheumatology, Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, ⁴Rheumatology, Hospital Britanico, Buenos Aires, Argentina, ⁵Hospital Britanico, Buenos Aires, Argentina, ⁶Rheumatology, British Hospital, Buenos Aires, Argentina, ⁷rheumatology, Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁸Rheumatology Unit, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁹Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, ¹⁰Diaz Colodrero 2537 8° A, Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, ¹¹Rheumatology Section, Hospital Señor del Milagro, Salta, Argentina, ¹²Rheumatology section, Hospital Señor del Milagro, Salta, Argentina, ¹³rheumatology, Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, ¹⁴Consultorio Privado, San Nicolás, Argentina, ¹⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina
Background/Purpose : Treatment adherence is a crucial part of successfully managing rheumatic diseases such as Rheumatoid Arthritis (RA). Low adherence to treatment has been related…
Abstract Number: 322 • 2014 ACR/ARHP Annual Meeting
Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis
Anderson Gaweco^1,2, Samantha Palmer¹, Rambon Shamilov¹, Caroline Stremnitzer¹, Katie Matthews¹, Michael Fisher¹, William Windsor¹, James Blinn¹, Ellen M. Ginzler³ and Jefferson Tilley¹, ¹Innovimmune Biotherapeutics, Brooklyn, NY, ²SUNY-Downstate Medical Center, Brooklyn, NY, ³Rheumatology, SUNY-Downstate Medical Center, Brooklyn, NY
Background/Purpose: T helper 17 [TH17] cells and its production of TH17 cytokines IL-17A and IL-17F play a critical role in the pathogenesis of RA and…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 2037 • 2014 ACR/ARHP Annual Meeting
Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population
Neil Accortt¹, Mary Anthony¹, Jennifer Schenfeld², Travis Wheeling², Anna Hassebroek², Cynthia O'Malley¹ and Michael Sprafka¹, ¹Center for Observational Research, Amgen, Inc., Thousand Oaks, CA, ²Docs Global, Inc, North Wales, PA
Background/Purpose: There is a dearth of information on the incidence rate of myasthenia gravis (MG) in the US and specifically among rheumatoid arthritis (RA) patients. …
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
Abstract Number: 2029 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study
Helga Radner^1,2, Kazuki Yoshida^3,4, Ihsane Hmamouchi⁵, Maxime Dougados^6,7, Josef Smolen⁸ and Daniel H Solomon⁹, ¹Department of Internal Medicine III; Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, Kamogawa, Japan, ⁴Division of Rheumatology, Brigham and Women’s Hospital, Boston, MA, ⁵Biostatistics, Epidemiology LBRCE, Mohamed V Souissi University, Rabat, Morocco, ⁶Descartes University, Cochin Hospital, Paris, France, ⁷INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, ⁸Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁹Rheumatology, Brigham and Women's Hospital, Boston, MA
Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-sectional StudyBackground/Purpose The presence of multimorbidity could lead to less intensive treatment of RA.…
Abstract Number: 1903 • 2014 ACR/ARHP Annual Meeting
Change in 14-3-3η Expression in Early RA Patients Treated with Dmards Corresponds with Change in DAS28 and Good EULAR Responses
Dirkjan van Schaardenburg¹, Mairead Murphy², Yuan Gui², Samina Turk³, Walter P. Maksymowych⁴ and Anthony Marotta⁵, ¹Dr Jan van Breemenstraat 2, Reade, Amsterdam, Netherlands, ²Augurex Life Sciences Corp., North Vancouver, BC, Canada, ³Reade, Amsterdam, Netherlands, ⁴Medicine/Rheumatic Dis Unit, University of Alberta, Edmonton, AB, Canada, ⁵1423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada
Background/Purpose 14-3-3η is a mechanistic marker that up-regulates inflammatory and joint damage factors that are implicated in the RA pathophysiological process1. It is a potent…
Abstract Number: 1847 • 2014 ACR/ARHP Annual Meeting
Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate in the Preserve Study
Josef Smolen¹, David Collier², Annette Szumski³, Heather Jones⁴ and Lisa Marshall⁵, ¹PsAID taskforce, EULAR, Zurich, Switzerland, ²Amgen, Inc., Thousand Oaks, CA, ³Specialty Care, Pfizer Inc., Collegeville, PA, ⁴Inflammation & Immunology, Pfizer Inc., Collegeville, PA, ⁵Inflammation Immunology Disease Group, Pfizer Inc., Collegeville, PA
Background/Purpose Previous studies evaluating various treatment strategies indicate that disease duration is a key determinant of outcomes in rheumatoid arthritis (RA). While data suggest that…
Abstract Number: 1540 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population
Brian Sauer¹, Chia-Chen Teng¹, Tao He¹, Jianwei Leng², Chao-Chin Lu¹, Neel Shah³, David J. Harrison⁴, Derek Tang⁴ and Grant W. Cannon⁵, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Salt Lake City VA and University of Utah, Salt Lake Citty, UT, ³1 Amgen Center Dr, Amgen Inc., Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: Biologics used for rheumatoid arthritis (RA) and ankylosing spondylitis (AS), including tumor necrosis factor blockers, are a key area of focus for Veterans Affairs…
Abstract Number: 1514 • 2014 ACR/ARHP Annual Meeting
An Analysis of in-Vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically-Meaningful Concentrations
M.E. Dowty, T.S. Lin, L. Wang, J. Jussif, B. Juba, L. Li, E. Moy and J.-B. Telliez, Pfizer Worldwide R&D, Cambridge, MA
Background/Purpose: A number of Janus kinase (JAK) inhibitors are being actively investigated for treatment of rheumatoid arthritis (RA), including tofacitinib, baricitinib, filgotinib (GLPG0634), and decernotinib…
Abstract Number: 482 • 2013 ACR/ARHP Annual Meeting
Methotrexate Use At Infliximab Initiation and Impact On Treatment Outcomes: An Analysis From A Canadian Registry
Denis Choquette¹, J. Carter Thorne², John T. Kelsall³, Michel Zummer⁴, Michael Starr⁵, Maqbool K. Sheriff⁶, William G. Bensen⁷, Andrew Chow⁸, Philip Baer⁹, Emmanouil Rampakakis¹⁰, John S. Sampalis¹⁰, Francois Nantel¹¹, Allen J. Lehman¹², Susan M. Otawa¹² and May Shawi¹³, ¹Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁴Rheumatology, Ch Maisonneuve-Rosemont, Montreal, QC, Canada, ⁵Montreal General Hospital, Montreal, QC, Canada, ⁶Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁷Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Private Practice, Scarborough, ON, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹³Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: Clinical trials of anti-TNF therapies have shown that concurrent methotrexate (MTX) therapy enhances the efficacy of infliximab (IFX)1. Data on the benefits of combination…
Abstract Number: 453 • 2013 ACR/ARHP Annual Meeting
Impact Of Inadequate Adherence On Clinical Outcomes: Results From The Biologics In Rheumatoid Arthritis Genetics and Genomics Study Syndicate Cohort
James Bluett¹, Catharine Morgan¹, Layla Thurston², Darren Plant¹, Ann W. Morgan³, Anthony G. Wilson⁴, John Isaacs⁵, Kimme L. Hyrich¹, Lis Cordingley¹ and Anne Barton¹, ¹Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, ²Manchester Medical School, The University of Manchester, Manchester, United Kingdom, ³NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁴Department of Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ⁵National Institute for Health Research, Newcastle Biomedical Research Centre, Newcastle Hospitals Foundation Trust and Newcastle University, Newcastle Upon Tyne, United Kingdom
Background/Purpose: Biologic therapy has revolutionised patient prognosis in rheumatoid arthritis (RA). In the UK, continuing biologic therapy requires a sustained response as determined by the…
Abstract Number: 2811 • 2013 ACR/ARHP Annual Meeting
Disease Characteristics and Treatment Patterns In US Veterans With Rheumatoid Arthritis and Concomitant Hepatitis C Infection
Ruchika Patel¹ and Joshua Baker², ¹Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Medicine/Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The prevalence of concurrent rheumatoid arthritis (RA) and hepatitis C (HCV) is estimated at 0.02%, affecting around 40,000 Americans. To our knowledge, no existing…
Abstract Number: 2663 • 2013 ACR/ARHP Annual Meeting
Moving Towards Personalized Healthcare: A Patient Reported Outcome Based Algorithm Can Aid Rheumatologists and Patients In Monitoring Rheumatoid Arthritis In Daily Clinical Practice
Jos Hendrikx¹, Jaap Fransen², Alessandro Toniolo³ and Piet L.C.M. van Riel⁴, ¹Rheumatology (470), Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Pfizer Pharmaceuticals, Rome, Italy, ⁴Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Several Patient Reported Outcome (PRO)-based instruments to measure disease activity in Rheumatoid Arthritis (RA) exist, though an evidence base for their use in monitoring…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.